TACL Temsirolimus ALL/NHL study

T2014-001: A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
To test a new experimental drug Temisirolimus - Temsirolimus (also known as Torisel®) is approved for kidney cell cancer treatment in adults - in combination with approved chemotherapy drugs - in the hopes of finding a drug combination that may be effective against leukemia and non-hodgkin’s lymphoma that has come back after initial treatment. To find the highest dose that can be given without casing severe side effects.
CHLA IRB Number
CHLA-14-00453
Study Type
Drug Treatment
Eligibility
Age 1 to 21 with leukemia (ALL) or NHL that has returned after an initial response to treatment
Clinical Trials Government Identifier
NCT01614197
Enrollment Status
Closed
Does this study also recruit healthy volunteers?
No
Coordinator Contact
Ellynore Florendo
Contact Email
TACL@chla.usc.edu